GSK announces $30 billion investment in US R&D and manufacturing

GSK plc (LSE/NYSE:GSK) announced Wednesday plans to invest $30 billion in research and development and supply chain infrastructure across the United States over the next five years. The announcement was made in a press release statement filed with the Securities and Exchange Commission.

The investment includes a new $1.2 billion commitment to advanced manufacturing facilities, artificial intelligence, and digital technologies. According to the company, this will support the creation of hundreds of highly skilled jobs in the US.

A significant portion of the new investment will fund the construction of an additional biologics manufacturing facility in Upper Merion, Pennsylvania. Construction of this facility is scheduled to begin in 2026. The company stated that the facility will focus on medicines for respiratory diseases such as COPD and asthma, as well as treatments for cancer, including hematological, gynecological, lung, and other solid tumors.

Additional funds will be allocated to upgrade AI and digital capabilities across GSK’s five existing manufacturing sites in Pennsylvania, North Carolina, Maryland, and Montana. The investment also covers new drug substance manufacturing capabilities and enhancements to device and auto-injector production.

GSK reported that the $30 billion investment will also increase R&D drug discovery, development, and clinical trial activity in the US. The company expects the US to lead globally in the number of studies, sites, and clinical trial participants conducted by GSK over the next five years.

The company noted that it has committed approximately $2 billion in new US manufacturing investments over the past 12 months, including the construction of a new $800 million facility in Marietta, Pennsylvania, which began in October 2024.

GSK employs about 15,000 people in the US. The company stated that these new investments will add several hundred skilled positions to its workforce.

The information in this article is based on a press release statement filed with the SEC.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.